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1. Introduction 
One of the most commonly diagnosed cancers is non-small cell lung cancer (NSCLC), which 
is the leading cause of lung cancer related deaths throughout the world 1;2. NSCLC is an 
aggressive tumor having poor surveillance. Patients with NSCLC have only 15% or less five 
year survival rate 3. Many genetic abnormalities involved in the pathogenesis of NSCLC e.g. 
mutation in the p53 gene a tumor suppressor gene. 
Chemokines; a superfamily of cytokines, low molecular weight (8-10kDa) proteins, are 
chemo-attractants for leukocytes and chemokines contains more than 40 ligands and 20 
receptors 4;5. Chemokines can be grouped into four sub families on the basis of the first two 
of four conserved cysteine residues, functional activity and receptor binding properties and 
are abbreviated as C, CC, CXC and CX3C. 
C chemokines or γ chemokines contains only two cysteines residues; one cysteine present at 
amino terminal and second present downstream, present in thymus and are 
chemoattractant for T cell precursors. 
CC chemokines are also called as ß-chemokines, have two adjacent cysteines at their N-
terminal. These proteins induce the migration of immune cells, mainly dendritic cells, 
natural killer cells and monocytes. 
CXC chemokines or α-chemokines are those in which single amino acid separates two 
adjacent cysteines present at N- terminal, thus have an "X" in their name. These are divided 
into two groups, ELR positive and ELR-negative. 
In CX3C chemokines or d-chemokines, two cysteines are separated by three amino acids. It 
acts in an autocrine manner i.e. secreted and act on the same cell.  
Chemokines have an important role in pro-inflammatory as well as non-inflammatory cell 
homing 6. Chemokines cause the migration of leukocytes to inflammatory sites and also play 
role in the hematopoietic stem cells regulation, angiogenesis and the extracellular matrix. 
This super-family also plays additional role in diverse fields including development, 
immunology and cancer. 
                                                                          




Chemokines also play an important role in the neoplastic transformation of a cell, encourage 
angiogenesis, tumor colonial expansion and changes in EMC and also mediate organ 
specific metastasis during carcinogenesis 7;8. Tumor metastatic potential can be determined 
by the tumor microenvironment and target organs 9;10. 
Chemokine receptors are G protein coupled receptors and numerous cells show the 
expression of these receptors including leukocytes, endothelial cells, stromal cells, epithelial 
cells and tumor cells 10-12. These receptors have vital roles in malignant tumor and 
cardiovascular diseases, also play role in allergic reactions, tissue damage and microbial 
infections 13;14. Chemokine receptors are classified into four subfamilies on the basis of four 
subfamilies of chemokines they bind, CXCR, CCR, CX3CR and XCR.  
Chemokine receptors play major role in tumor metastasis 14-16. At each step of metastasis 
these receptors potentially facilitate tumor dissemination. In order to estimate the clinical 
significance of these receptors few clinical studies have been done. But there is no 
comprehensive study regarding all the chemokine receptors in NSCLC 17-19. 
2. Expression of CXCL8 in NSCLC 
In cancers having angiogenic phenotypes like NSCLC, CXCL8 is a very effective and 
powerful angiogenic factor. Its receptors are CXCR1 and CXCR2 20.Tumor angiogenesis, 
metastasis and poor survival rate is related to high level of CXCL8 21-23. 
CXCL8 directly promotes proliferation of endothelial cell, chemo taxis and tubular 
morphogenesis 24-26. CXCL8 was identified in a gene expression of patients that were 
predictive of poor prognosis with stage 1 lung cancer 7;27. 
Two of the six cell lines of NSCLC expressed high levels of CXCL8, these cell lines are A549 
and H441, while the other cell lines expressed low levels of CXCL8. Earlier studies assumed 
that only cancer cells produce CXCL8. However stromal cells secrete high level of CXCL8 
and also increase tumor cells in tumor and stromal cells co-culture. Mechanism of this 
induction is still undefined. In several in-vitro models, cell to cell contact is involved in the 
induction of CXCL8 20. Role of CXCL8 in lung cancer is not obvious. CXCL8 receptors are 
present on lung cancerous cells but their effect on tumor angiogenesis and proliferation is 
still uncertain. 
CXCR1 is a major receptor of CXCL8 which allows or influence the mitogenic activity of it in 
NSCLC. Thus, targeting mitogenic and angiogenic activity of CXCL8 may help to control 
tissue invasion and metastasis of NSCLC 20. Circulating human CXCL8 can be a valuable, 
clinically applicable tumor protein marker owed to its affirmative correlation by means of 
numerous physiologic variables related by lung cancer progression. 
3. Expression of CXCL5 & CXCL12 in NSCLC 
CXCL5 is an important mediator of angiogenesis in NSCLC. In different experimental 
studies, it is observed that angiogenesis in NSCLC is directly correlated to higher level of 
CXCL5 28. 
Surgical specimens of NSCLC show a direct link between tumor angiogenesis and CXCL5. 
In SCID mice, CXCL5 expression was directly related to tumor proliferation and metastasis.  
www.intechopen.com
 
Chemokines & Their Receptors in Non-Small Cell Lung Cancer Detection 79 
Reduction of CXCL5 expression, reduce tumor proliferation and metastases 28.This was also 
suggested by recent studies that the presence of CXCL5 in NSCLC have higher degree of 
correlation with both tumor proliferation and patient prognosis 21;29. 
CXCL12 with CXCR4 had also been involved in stimulating angiogenesis of NSCLC 30;31. 
However, recent experimental studies of NSCLC make it clear that CXCR4 is expressed on 
cancerous cells and does not stimulate tumor angiogenesis in an in vivo culture. In this 
experimental study, with reduction of CXCL12 level, no significant change in primary 
tumor size and tumor angiogenesis was observed 32. 
However, there is an obvious reduction of metastasis of these tumors into in vitro culture, 
indicating that the CXCL12/CXCR4 promotes metastasis and proliferation of the tumor cells. 
A reason for this noticeable difference of these in vivo studies from other in vitro studies of 
angiogenesis mediated by CXCL12/CXCR4 is that CXCR4 expressing tumor cells can 
“outcompete” tumor-associated endothelial cells for CXCL12. Therefore, there is a very great 
difference in the function of CXCL12 against the other factors associated with angiogenesis, 
such that metastasis is promoted by CXCL5, CXCL8, and vascular endothelial growth factors. 
CXCL5 & CXCL12 receptors over expression in tumor tissues possibly will suggest the 
development of diagnostic agents and therapy targeted at chemokine receptor–over 
expressing tumors. In this regard only some exhaustive clinical studies have been 
undertaken to assess the clinical importance of these receptors status but no comprehensive 
study has been known in NSCLC. 
4. Expression of CXCR1& CXCR2 
There are two cell surface receptors which bind to CXCL8, known as CXCR1 and CXCR2; 
these receptors have similar structure but different binding sites 33. CXCR1 binds only with 
one CXC chemokine, CXCL8, while CXCR2 binds to numerous CXC chemokines. These 
receptors are present on different cell types including leukocytes, keratinocytes, endothelial 
cells 34;35 and various tumor cells including NSCLC36;37.  
When functions of CXCL8 and importance of its receptors, CXCR1 and CXCR2 were 
observed in different cancer cell lines, it was found that an increased level of CXCL8 
mediated cell invasion and migration is directly correlated with increased expression of 
CXCR1 &CXCR2. By using different neutralizing antibodies, it was observed that CXCR1 
was not involved in cell migration and invasion, only CXCR2 was involved, while both 
receptors are involved in angiogenesis. Thus making strategies against CXCL8 signaling 
pathways promises a better therapy of cancer. It is demonstrated by several studies that 
CXCR2 is responsible for CXCL8 mediated angiogenesis in NSCLC and human micro 
vascular endothelial cells 24;38;39. 
CXCR1 is an important receptor which promotes the function of CXCL8. Thus targeting 
expression of CXCR1 & production of CXCL8 may ultimately help to develop strategies 
against lung cancer proliferation, invasion and metastasis.  
5. Expression of CXCR4 
CXCR4 is receptor for chemokine CXCL12. In NSCLC, tumor cells at stage 1 show 




studies on tumor cells show that CXCR4 positive nuclear staining is related with improve 
survival rate. The 5 year overall survival rate was 93% for the patients having strong nuclear 
staining 52% for those having weak nuclear staining 10. 
CXCL12 and its receptor CXCR4 promote metastasis of different tumors having angiogenic 
phenotype including NSCLC 17;32;40-42.CXCR4 may transform a benign tumor to malignant 
phenotype 17;43. 
6. Expression of CXCR7 
It was previously thought that CXCL12 has only one surface receptor, CXCR4, but Burns 
and colleagues 14;44 characterized that another receptor CXCR7 binds CXCL12. CXCR7 
together with CXCR3 also has another ligand CXCL11. CXCR7 presents on many cell lines 
including cancer cell lines, fetal liver cells and activated endothelial cells. It facilitates 
angiogenesis and the blockage of CXCR7 inhibits tumor growth in mouse models. 
Patients with EGFR gene mutations show high level of CXCR7 expression. Choi and 
colleagues reported that mutations in one EGFR domain, tyrosine kinase are responsible for 
phosphorylation of EGFR, tyrosine independent mutations and caused constant activation 
of EGFR 14;45. 
Molecular analysis of tumor of patients that took part in the TRIBUT or IDEAL/INTAC 
experimental study revealed that patients with improve prognosis had an EGRF mutated 
tumor. This is one of the explanations that CXCR7 is an independent disease free prognostic 
factor 14. 
Wang and colleagues by using qualitative mRNA characterized that increasing tumor grade 
show increased expression of CXCR7 in prostate cancer. Fluorescence activated cell sorting 
analysis also indicated higher CXCR7 expression 46. 
In conclusion higher expression of CXCR7 is linked with tumor metastasis and poor 
survival of patients with P-stage1 NSCLC. As the elevated CXCR7 expression is directly 
correlated with increased EGFR gene mutations, therefore the expression of CXCR7 is not 
the only one factor for overall survival. We can also say that in future, studies of CXCR7 
possibly will lead on the road to the development of diagnostic agents and targeted therapy 
for patients with p-stage I NSCLC. 
7. Expression of receptors in tumor islets 
Survival of NSCLC patients is directly related to CXCR2, CXCR3 and CXCR4 expression in 
tumor stroma. Expression of CXCR3 and CCR1 is also positively correlated to increase in 
number of mast cells and islet macrophages. The chemokine receptor CCR1 is present on 
macrophages and involved in the migration of macrophages into tumor islets. CCR1 is a 
receptor of CCL3 protein. TNF-α production and release is stimulated by CCL1 and has 
cytotoxic potential in tumor islets. Natural killer cells, T lymphocytes and mast cells show 
the expression of CXCR3; there is no evidence of expression of CXCR3 on macrophages 4;47-
49. These immune cells are linked with increase survival in NSCLC and together with 
macrophages involved tumor killing 4;19;50;51. 
The tumors enriched for cells expressing CXCR3, having large quantities of one or all of the 
CXCR3 binding chemokines including CXCL9, CXCL10 and CXCL11. Host anti tumor 
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immune response is mediated by expression of CXCR3 on various immune cells in mouse 
model. CXCR3 binding chemokines are secreted by a variety of inflammatory and structural 
cells and act as indicating markers for Th1 immunological 4;52. 
In NSCLC, CCL5 produced by tumor epithelial cells and involved in determination of the 
nature and intensity of the immune response. While CXCR2 is not expressed in epithelial 
cells of the tumor islets, but is expressed on inflammatory cells. Expression of CXCR2 is 
directly correlated with increased survival. So it is suggested that neoplastic transformation 
is promoted by reduction of CXCR2 expression on epithelial cells in NSCLC. It is also 
suggested that expression of CXCR2 on inflammatory cells used to limit tumor proliferation. 
There is dichotomy in function of CXCR2 in NSCLC.  In the stroma, it acts as an angiogenic 
factor and helps in tumor proliferation, but on the other side by the recruitment of the 
inflammatory cells to tumor islet, it limits tumor growth. Thus targeting CXCR2 has 
unpredictable effects depending on the relative balance between these two different 
functions 4. 
Conclusively, this information can be considered to target the chemokines and chemokine 
receptors to establish the therapeutic strategies and to confine the tumor microenvironment 
to minimize the possibility of metastasis. 
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